Seòmar agus comataidhean

The Scottish Government, as Sponsor, works closely with ILF Scotland on financial monitoring to ensure that funds are available to meet operational requirements whilst not being provided in advance of need or building up large reserves balances. This is consistent with the Scottish Public Finance Manual. In the current financial year, the Scottish Government has provided £47.72 million to ILF Scotland which covers the funding requirement for 2022-23. Financial reserves, held by ILF Scotland that are in excess of minimum requirements, have been used in addition to funds made available by the Scottish Government to meet operational demands.

The Independent Living Fund was transferred to ILF Scotland on 1st July 2015, and at that time:

(a) 2,812 people resident in Scotland were in receipt of the Fund.

(b) The total budget to continue financial awards for people resident in Scotland for the remainder of the financial year 2015-16 was £36.34 million (equivalent to a full year cost of £48.45 million).

Whilst Scottish Government do not hold the information requested centrally, we are progressing work to allow Boards to automatically gather this.

We know that endometriosis can have a significant impact on people’s lives, and that support for those with the condition is required while we work to improve waiting times.  

To ensure those with endometriosis are receiving consistent and appropriate care we will help support The Modernising Patient Pathways Programme (MPPP) to implement the new Integrated Endometriosis Referral Care Pathway for NHS Scotland, which has now been approved and will be circulated to all NHS Scotland health boards this year.  

We have invested in research into endometriosis, which is vital to help us achieve better care for those with the condition. We are jointly funding a £250,000 endometriosis research project with Wellbeing of Women and the recipient of the grant will be announced later in March. The research aims to develop improvements into treatment and management options for the condition.  

To ensure that people with endometriosis have access to the most accurate and relevant information and links to further support, we updated the NHS Inform endometriosis page. This includes videos to support those with the condition and to provide information about symptoms and treatment options available.  

The supply of medicines is a reserved matter for the UK Government. Scottish Government officials are regularly updated on any supply disruptions which may arise and will provide advice to the NHS in Scotland on options to address any shortages.      

In partnership with the Scottish Strategic Network for Genomics Medicine (SSNGM), we have been developing our Strategic Intent for Genomics Medicine which will be published in the coming weeks.

While early in its’ development, we will also publish our first Genomics Strategy for Scotland and associated implementation plan in the course of 2023.

Official statistics for the Scottish Cervical Screening Programme will be published this Spring, with data up to March 2022. It is therefore too early to assert what uptake for 2021/22 will show, however the Scottish Government is aware that previous years have highlighted the need to improve uptake.

Both the Scottish Government and the Cervical Screening Programme encourage all those eligible for cervical screening to go for a test when invited, and for all those eligible to take up the offer of the HPV vaccine when invited to.

We continue to work with Jo’s Cervical Cancer Trust to support their vital campaign work on cervical cancer, having awarded £456,000 in funding to highlight the benefits of screening and to better understand barriers to uptake.

Finally, we understand that increasing uptake alone is not enough, and that we must also strive for equality of uptake. Work is currently underway on a national Equity in Screening Strategy, which is being led by National Screening Oversight. The strategy will provide a focus and commitment to tackle inequalities in screening, to achieve equity of access for all eligible individuals across the whole screening pathway. It will consider the main causes of inequalities and will outline initial actions to address barriers and facilitate access of underserved groups.

The Scottish Government recognises that an improved streamlined process for the implementation of new genetic tests linked to a Scottish Medicines Consortium (SMC) approved medicine is required. The SMC currently provides early information to National Services Division (NSD) on cancer medicines in clinical development that are expected to require a companion diagnostic through regular horizon scanning reports. To support financial and service planning, the SMC also provides Health Boards – in confidence - with information on medicines that may require a companion diagnostic through regular Forward Look reports, which include emerging new medicines, including Advanced Therapy Medicinal Products (ATMPs).

A key function of the Scottish Strategic Network for Genomics Medicine (SSNGM) is to horizon scan for new medicines to prevent delays for patients getting access to advanced therapies. To support this, the SSNGM has established Scottish Genomics Testing Assessment Groups (SGTAG) for cancer and rare disease. The SGTAG will work with the SMC and others to approve the availability of companion diagnostic tests in the genetic laboratories.

The following table details the precision medicines accepted by the Scottish Medicines Consortium where the companion diagnostic test is not yet offered by NHS Scotland laboratories, and the anticipated roll-out of the appropriate test.

Validation is required for every companion diagnostic test to ensure the accuracy of the test meets the indication required. A number of tests have completed validation and are currently awaiting implementation throughout the course of 2023. We continue to work with key partners, such as the Scottish Strategic Network for Genomics Medicine (SSNGM), to ensure there is capacity within laboratories for companion diagnostics tests.

*Olaparib (SMC2366) for the treatment of prostate cancer

**Olaparib (SMC2368) for the treatment of ovarian, fallopian tube or primary peritoneal cancer requires two companion diagnostics tests in order for patients to access the treatment. One of the tests, BRCA, is available in NHS Scotland labs, however, the other, HRD, is not available due to its complexity. While testing isn’t available in NHS laboratories, it is available through an alternative provider ensuring patients can still access the medicine.

The delivery of Scotland Genomics strategy is being overseen by the Scottish Strategic Network for Genomic Medicine (SSNGM). The Network is supported by a Scottish Government funded transformation team which is led by a Consultant Clinical Scientist and supported by Clinical Leads for rare disease and cancer.

The Network draws on a wide pool of stakeholders including clinicians and scientists. Many of which are supporting us directly to shape The Strategy through various working groups.

The responsibilities of Scottish Ministers and the Water Industry Commission for Scotland are set out in the Water Industry (Scotland) Act 2002, as amended. The Principles of Charging, available at https://www.gov.scot/publications/principles-of-charging-2021-2027/ , specify how Scottish Water is to charge for its services, together with the discounts, exemptions and reductions which must be applied.